Stay updated with breaking news from Startup Stocks. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tensions over the shadowy and often enigmatic market of private company stocks have reached a boiling point, just as the buying and selling of such shares has grown bigger than ever. At its center is an age-old debate: Should everyone have access to the riches and risks of investing in Silicon Valley startups?
“As the tone of the market is sideways, defensive stocks are outperforming and there is the traction which we can see. So, Glaxo can be bought at Rs 1640; Rs 1540 should be the stop loss and Rs 1,745 to 1,850 should be the target. The second one, Glenmark, is again from defensive space. It can be bought at Rs 793; Rs 740 should be the stop loss and Rs 900 to 1,000 should be the target.”